# A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors

> **NCT07115043** · PHASE1,PHASE2 · RECRUITING · sponsor: **AstraZeneca** · enrollment: 60 (estimated)

## Conditions studied

- Melanoma
- Non-small Cell Lung Cancer
- Squamous Cell Carcinoma (Skin)
- Renal Cell Carcinoma
- Merkel Cell Carcinoma
- Triple Negative Breast Cancer
- Head and Neck Squamous Cell Carcinoma
- Gastric Cancer/Gastroesophageal Junction Cancer
- High Grade Serous Ovarian Carcinoma

## Interventions

- **DRUG:** AZD6750
- **DRUG:** rilvegostomig

## Key facts

- **NCT ID:** NCT07115043
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-07-29
- **Primary completion:** 2029-10-02
- **Final completion:** 2029-10-02
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2026-04-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07115043

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07115043, "A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT07115043. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*